1
|
Wang L, Song L. Identification of immune cell infiltration profiles in renal cell carcinoma and their clinical significance. Medicine (Baltimore) 2023; 102:e33732. [PMID: 37171354 PMCID: PMC10174390 DOI: 10.1097/md.0000000000033732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/13/2023] Open
Abstract
Renal cell carcinoma (RCC) is the most common malignancy of the urinary system, accounting for 3.7% of all new malignancies. The prognosis of RCC patients is still poor, especially patients in advanced stage. Limited studies have fully clarified the role of immune cell infiltration profiles in the prognosis and immunotherapy of RCC. In current study, we evaluated the abundance of the 22 tumor-infiltrating immune cells (TIICs) with CIBERSORT methods. The correlation between TIICs and clinicopathological parameters, tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS) of RCC patients were also explored. Significant correlations were obtained between TIICs subpopulation and specific clinicopathologic parameters of RCC, including age, gender, tumor grade, clinical stage, T stage and distant metastasis. Moreover, RCC patients with high level of memory activated CD4 T cells, follicular helper T cells and regulatory T cells had a worse overall survival (OS) rate. RCC patients with high level of CD 8 + T cells and M1 macrophages had a lower TIDE score and higher anti-CTLA IPS, higher anti-PD1 IPS as well as higher anti-PD1/CTLA4 IPS. Our results clarified the immune cell infiltration profiles of RCC. RCC patients with high level of CD 8 + T cell and M1 macrophages had a lower TIDE score and higher IPS, suggesting that RCC patients with high level of CD 8 + T cell and M1 macrophages may benefit from immunotherapy.
Collapse
Affiliation(s)
- Le Wang
- Department of Blood Transfusion, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Lei Song
- Department of General Practice, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| |
Collapse
|
2
|
Xu J, Zhang R, Peng Q, Jia Z, Xiao S, Sun N, Peng M. The profile and prognostic value of circulating lymphocyte subsets in metastatic colon cancer. Int Immunopharmacol 2023; 117:109848. [PMID: 36812670 DOI: 10.1016/j.intimp.2023.109848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 02/01/2023] [Accepted: 02/02/2023] [Indexed: 02/22/2023]
Abstract
OBJECTIVE Colon cancer (CC) are the most common malignant cancer in human digestive system, however, the profile and prognostic value of circulating lymphocyte subsets in CC patients has not been systemically clarified. METHODS In this study, 158 patients with metastatic CC were enrolled. Chi-square test was used to analyze the relationship between baseline peripheral blood lymphocyte subsets and clinicopathological parameters. Kaplan-Meier and Log-rank tests were used to analyze the relationship between clinicopathological parameters and baseline peripheral lymphocyte subsets and overall survival (OS) of patients with metastatic CC. Univariate/multivariate COX regression analysis was used to identify the independent factors in metastatic CC. RESULTS The baseline peripheral blood CD3+T cells, CD4+T cells, NK cells and B cells of BRAF mutant patients were significantly lower than those in BRAF wild-type patients; The baseline CD8+T cells of KRAS mutation group was lower than that in KRAS wild type group. Peripheral blood CA19-9 > 27, left-sided colon cancer (LCC), KRAS and BRAF mutation were poor prognostic factors, and ALB > 40, NK cells were protective prognostic factors for metastatic CC. In patients with liver metastases subgroup, higher NK cells also indicated a longer OS. Finally, LCC (HR = 0.56), CA19-9 (HR = 2.13), ALB (HR = 0.46) and circulating NK cells (HR = 0.55) were independent prognostic factors for metastatic CC. CONCLUSION LCC, higher level of ALB and NK cells at baseline are protective factors, and higher CA19-9, KRAS/BRAF gene mutation are adverse prognostic factors. Sufficient circulating NK cells are independent prognostic factor for metastatic CC patients.
Collapse
Affiliation(s)
- Juan Xu
- Department of Oncology, Suqian Zhongwu Hospital/Suqian Cancer Hospital, Suqian 223800, Jiangsu, China
| | - Ruru Zhang
- Department of Oncology, Suqian Zhongwu Hospital/Suqian Cancer Hospital, Suqian 223800, Jiangsu, China
| | - Qing Peng
- Department of Oncology, Suqian Zhongwu Hospital/Suqian Cancer Hospital, Suqian 223800, Jiangsu, China
| | - Zhenghu Jia
- Guangzhou Purui Biotechnology Co., Ltd., Guangzhou 510660, Guangdong, China; The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou 510632, Guangdong, China
| | - Shuang Xiao
- Guangzhou Purui Biotechnology Co., Ltd., Guangzhou 510660, Guangdong, China; The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou 510632, Guangdong, China
| | - Niangen Sun
- Department of Oncology, Suqian Zhongwu Hospital/Suqian Cancer Hospital, Suqian 223800, Jiangsu, China.
| | - Mengqing Peng
- Department of Oncology, Suqian Zhongwu Hospital/Suqian Cancer Hospital, Suqian 223800, Jiangsu, China.
| |
Collapse
|
3
|
TRIM27 is an adverse prognostic biomarker and associated with immune and molecular profiles in right-sided colon cancer. Am J Cancer Res 2022; 12:4988-5003. [PMID: 36504896 PMCID: PMC9729902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 10/26/2022] [Indexed: 12/15/2022] Open
Abstract
Right-sided colon cancer (RCC), as an independent tumor entity, shows a poor prognosis. It is imperative to detect immune microenvironment-related genes for predicting RCC patient prognosis and study their function in RCC. Tripartite motif-containing 27 (TRIM27) was identified as a risk signature from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) datasets by using weighted gene co-expression network analysis, differentially expressed analysis, and univariate Cox analysis. It predicted a poorer overall survival and increased lymph node metastasis, which were then validated in our 48 clinical samples. Using immunohistochemistry, TRIM27 was found to be highly expressed in both cancer cells and surrounding immunocytes, and its expression in tumor or immune cells both predicted a poorer prognosis. Thereafter, the functional mechanism, immune and molecular characteristics of TRIM27 were investigated using gene set enrichment analysis (GSEA), ESTIMATE, CIBERSORT, and gene set variation analysis (GSVA) at the single-cell, somatic mutation, and RNA-seq level. Patients with highly expressed TRIM27 presented lower CD4+ T cell infiltration and activation of the mTORC1/glycolysis pathway. In addition, patients with highly expressed TRIM27 were characterized by hypermetabolism, higher tumor purity, more BRAF mutation, and more chromosomal instability. Collectively, TRIM27 is an important immune-related prognostic biomarker in patients with RCC. It may function via activating the mTORC1/glycolysis pathway and suppressing CD4+ T cells. These results indicated that TRIM27 could be a promising therapeutic target in RCC.
Collapse
|
4
|
Wu J, Cheng H, Wang H, Zang G, Qi L, Lv X, Liu C, Zhu S, Zhang M, Cui J, Ueno H, Liu YJ, Suo J, Chen J. Correlation Between Immune Lymphoid Cells and Plasmacytoid Dendritic Cells in Human Colon Cancer. Front Immunol 2021; 12:601611. [PMID: 33708200 PMCID: PMC7940519 DOI: 10.3389/fimmu.2021.601611] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 01/11/2021] [Indexed: 12/26/2022] Open
Abstract
Background Innate lymphoid cells (ILCs), so far studied mostly in mouse models, are important tissue-resident innate immune cells that play important roles in the colorectal cancer microenvironment and maintain mucosal tissue homeostasis. Plasmacytoid dendritic cells (pDCs) present complexity in various tumor types and are correlated with poor prognosis. pDCs can promote HIV-1-induced group 3 ILC (ILC3) depletion through the CD95 pathway. However, the role of ILC3s in human colon cancer and their correlation with other immune cells, especially pDCs, remain unclear. Methods We characterized ILCs and pDCs in the tumor microenvironment of 58 colon cancer patients by flow cytometry and selected three patients for RNA sequencing. Results ILC3s were negatively correlated, and pDCs were positively correlated, with cancer pathological stage. There was a negative correlation between the numbers of ILC3s and pDCs in tumor tissues. RNA sequencing confirmed the correlations between ILC3s and pDCs and highlighted the potential function of many ILC- and pDC-associated differentially expressed genes in the regulation of tumor immunity. pDCs can induce apoptosis of ILC3s through the CD95 pathway in the tumor-like microenvironment. Conclusions One of the interactions between ILC3s and pDCs is via the CD95 pathway, which may help explain the role of ILC3s in colon cancer.
Collapse
Affiliation(s)
- Jing Wu
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
| | - Hang Cheng
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
- Department of Pediatrics, The First Hospital, Jilin University, Changchun, China
| | - Helei Wang
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
- Department of Stomach Colorectal Anal Surgery, The First Hospital, Jilin University, Changchun, China
| | - Guoxia Zang
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
| | - Lingli Qi
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
- Department of Pediatric Gastroenterology, The First Hospital, Jilin University, Changchun, China
| | - Xinping Lv
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
| | - Chunyan Liu
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
- Department of Gynecology, The First Hospital, Jilin University, Changchun, China
| | - Shan Zhu
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
| | - Mingyou Zhang
- Department of Cardiovascular Center, The First Hospital, Jilin University, Changchun, China
| | - Jiuwei Cui
- Cancer Center, The First Hospital, Jilin University, Changchun, China
| | - Hideki Ueno
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Yong-Jun Liu
- Department of Research and Development of Sanofi, Cambridge, MA, United States
| | - Jian Suo
- Department of Stomach Colorectal Anal Surgery, The First Hospital, Jilin University, Changchun, China
| | - Jingtao Chen
- Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China
- Key Laboratory of Organ Regeneration & Transplantation of the Ministry of Education, The First Hospital of Jilin University, Changchun, China
| |
Collapse
|
5
|
Cancer Immunoimaging with Smart Nanoparticles. Trends Biotechnol 2020; 38:388-403. [DOI: 10.1016/j.tibtech.2019.11.001] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 10/30/2019] [Accepted: 11/05/2019] [Indexed: 12/31/2022]
|
6
|
Pan QZ, Gu JM, Zhao JJ, Tang Y, Wang QJ, Zhu Q, Song MJ, Li YQ, He J, Chen SP, Weng DS, Xia JC. Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer. Clin Transl Immunology 2020; 9:e1113. [PMID: 32076550 PMCID: PMC7029432 DOI: 10.1002/cti2.1113] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2019] [Revised: 02/03/2020] [Accepted: 02/03/2020] [Indexed: 12/14/2022] Open
Abstract
Objectives Fluoropyrimidine‐based chemotherapy regimens are the current first‐line treatment for metastatic colorectal cancer (mCRC); however, the outcome is often unsatisfactory. The present study aimed to determine the effect of combined cytokine‐induced killer (CIK) cell immunotherapy and first‐line chemotherapy in patients with mCRC. Methods This retrospective study included 252 patients with mCRC treated with first‐line chemotherapy. Among them, 126 patients received first‐line chemotherapy only (control group), while the other 126 patients, with similar demographic and clinical characteristics, received CIK cell immunotherapy combined with first‐line chemotherapy (CIK group). Overall survival (OS) and progression‐free survival (PFS) were compared between the two groups using the Kaplan–Meier method. Results The median OS for the CIK group was 54.7 versus 24.1 months for the controls, and the median PFS for the CIK group was 25.7 versus 14.6 months for the controls. Univariate and multivariate analyses indicated that CIK cell treatment was an independent prognostic factor for patients' OS and PFS. Subgroup analyses showed that CIK cell treatment significantly improved the OS and PFS of patients with metastatic colon cancer, but not those with metastatic rectal cancer. Additionally, the change in CD3+CD56+ subsets after the fourth treatment cycle might be an indicator of successful CIK cell treatment: Patients with increased CD3+CD56+ subsets had better survival than those with decreased CD3+CD56+ subsets. Conclusion Cytokine‐induced killer cell immunotherapy combined with first‐line chemotherapy could significantly improve the OS and PFS of patients with mCRC, particularly for patients with metastatic colon cancer.
Collapse
Affiliation(s)
- Qiu-Zhong Pan
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China.,Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Jia-Mei Gu
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China.,Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Jing-Jing Zhao
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China.,Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Yan Tang
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China.,Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Qi-Jing Wang
- Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Qian Zhu
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China
| | - Meng-Jia Song
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China
| | - Yong-Qiang Li
- Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Jia He
- Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Shi-Ping Chen
- Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - De-Sheng Weng
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China.,Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| | - Jian-Chuan Xia
- State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-Sen University Cancer Center Guangzhou China.,Department of Biotherapy Sun Yat-Sen University Cancer Center Guangzhou China
| |
Collapse
|
7
|
Liu D, Sun X, Du Y, Kong M. Propofol Promotes Activity and Tumor-Killing Ability of Natural Killer Cells in Peripheral Blood of Patients with Colon Cancer. Med Sci Monit 2018; 24:6119-6128. [PMID: 30174326 PMCID: PMC6131980 DOI: 10.12659/msm.911218] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Background We investigated the effect of propofol on activities and tumor-killing ability of natural killer (NK) cells in patients with colon cancer. Material/Methods Twenty colon cancer patients and 20 healthy subjects were included. Peripheral blood (5 ml) was collected from all patients and healthy subjects. NK cells in peripheral blood were separated by negative screening using immunomagnetic beads. Flow cytometry was used to determine expression of activated receptors, inhibitory receptors, killing effector molecules, and proliferation-associated markers on NK cell surfaces. After in vitro treatment with propofol for 24 h, expression of activated receptors, inhibitory receptors, killing effector molecules, and proliferation-associated markers on NK cell surfaces was examined again. In addition, the tumor-killing effect of NK cells was studied by co-culture with K562 cells or colon cancer SW620 cells at a ratio of 1: 1. Results The number of NK cells in peripheral blood from colon cancer patients was increased compared with healthy subjects, but activities and proliferation ability of the NK cells were decreased. The tumor-killing effect of NK cells isolated from colon cancer patients was decreased. Of note, propofol promoted activation of NK cells from colon cancer patients. In addition, propofol increased expression of tumor-killing effector molecules by NK cells and the proliferation ability of NK cells. Propofol also enhanced the killing effect of NK cells on colon cancer cells. Conclusions The present study demonstrates that propofol promotes the activity and tumor-killing ability of NK cells in peripheral blood of patients with colon cancer.
Collapse
Affiliation(s)
- Dongshui Liu
- Department of Anesthesiology, Affiliated Hospital of Taishan Medical University, Taian, China (mainland)
| | - Xiaoshan Sun
- Department of Anesthesiology, Affiliated Hospital of Taishan Medical University, Taian, China (mainland)
| | - Yue Du
- Department of Anesthesiology, Affiliated Hospital of Taishan Medical University, Taian, China (mainland)
| | - Minmin Kong
- Department of Anesthesiology, Affiliated Hospital of Taishan Medical University, Taian, China (mainland)
| |
Collapse
|